# Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

> **NCT06046222** · PHASE2 · RECRUITING · sponsor: **NS Pharma, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Eosinophilic Granulomatosis With Polyangiitis
- Churg-Strauss Syndrome

## Interventions

- **DRUG:** NS-229
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06046222
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046222, "Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06046222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*